SI3176165T1 - Kristal derivata azol benzena kot inhibitor ksantin oksidaze - Google Patents

Kristal derivata azol benzena kot inhibitor ksantin oksidaze

Info

Publication number
SI3176165T1
SI3176165T1 SI201530420T SI201530420T SI3176165T1 SI 3176165 T1 SI3176165 T1 SI 3176165T1 SI 201530420 T SI201530420 T SI 201530420T SI 201530420 T SI201530420 T SI 201530420T SI 3176165 T1 SI3176165 T1 SI 3176165T1
Authority
SI
Slovenia
Prior art keywords
crystal
xanthine oxidase
oxidase inhibitor
benzene derivative
azole benzene
Prior art date
Application number
SI201530420T
Other languages
English (en)
Inventor
Asahi Kawana
Yuki Miyazawa
Original Assignee
Teijin Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Limited filed Critical Teijin Pharma Limited
Publication of SI3176165T1 publication Critical patent/SI3176165T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
SI201530420T 2014-07-30 2015-07-29 Kristal derivata azol benzena kot inhibitor ksantin oksidaze SI3176165T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014155031 2014-07-30
EP15827012.4A EP3176165B1 (en) 2014-07-30 2015-07-29 Crystal of azole benzene derivative as xanthine oxidase inhibitor
PCT/JP2015/071512 WO2016017696A1 (ja) 2014-07-30 2015-07-29 アゾールベンゼン誘導体の結晶

Publications (1)

Publication Number Publication Date
SI3176165T1 true SI3176165T1 (sl) 2018-11-30

Family

ID=55217594

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201530420T SI3176165T1 (sl) 2014-07-30 2015-07-29 Kristal derivata azol benzena kot inhibitor ksantin oksidaze

Country Status (30)

Country Link
US (1) US9815826B2 (sl)
EP (1) EP3176165B1 (sl)
JP (1) JP6230713B2 (sl)
KR (1) KR20170033321A (sl)
CN (1) CN106536519B (sl)
AR (1) AR101363A1 (sl)
AU (1) AU2015297489B2 (sl)
BR (1) BR112017001659A2 (sl)
CA (1) CA2955485A1 (sl)
CY (1) CY1120933T1 (sl)
DK (1) DK3176165T3 (sl)
ES (1) ES2693382T3 (sl)
HR (1) HRP20181789T1 (sl)
IL (1) IL250144B (sl)
LT (1) LT3176165T (sl)
MX (1) MX370375B (sl)
MY (1) MY179339A (sl)
NZ (1) NZ729045A (sl)
PH (1) PH12017500123B1 (sl)
PL (1) PL3176165T3 (sl)
PT (1) PT3176165T (sl)
RS (1) RS57797B1 (sl)
RU (1) RU2675854C2 (sl)
SA (1) SA517380786B1 (sl)
SG (1) SG11201700742UA (sl)
SI (1) SI3176165T1 (sl)
TR (1) TR201818775T4 (sl)
TW (1) TWI687418B (sl)
WO (1) WO2016017696A1 (sl)
ZA (1) ZA201700491B (sl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201300552D0 (en) * 2013-01-14 2013-02-27 Moog Bv Motion simulator
WO2016017826A1 (ja) * 2014-07-30 2016-02-04 帝人ファーマ株式会社 キサンチンオキシダーゼ阻害薬

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122008000051I1 (de) 1990-11-30 2009-02-05 Teijin Ltd 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
US5843969A (en) 1995-04-07 1998-12-01 Teijin Limited Protecting agent for organ or tissue
JP2002105067A (ja) 2000-09-28 2002-04-10 Teijin Ltd ２−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物
WO2004043400A2 (en) * 2002-11-14 2004-05-27 Celmed Oncology (Usa), Inc. Peptide deformylase activated prodrugs
CN101282936B (zh) * 2005-10-07 2012-05-16 橘生药品工业株式会社 氮化杂环化合物及包含其的药物组合物
WO2008126770A1 (ja) * 2007-04-05 2008-10-23 Astellas Pharma Inc. トリアリールカルボン酸誘導体の製造方法
CN101679244B (zh) * 2007-04-11 2014-01-01 橘生药品工业株式会社 5元杂环衍生物及其医药用途
WO2010018458A2 (en) 2008-08-12 2010-02-18 Crystalgenomics, Inc. Phenol derivatives and methods of use thereof
WO2010128163A2 (en) 2009-05-08 2010-11-11 Pike Pharma Gmbh Small molecule inhibitors of influenza a and b virus and respiratory syncytial virus replication
US20130190366A1 (en) 2010-02-19 2013-07-25 Cadila Healthcare Limited Substantially pure salts of febuxostat and processes for preparation thereof
US8969582B2 (en) 2010-04-29 2015-03-03 Dr. Reddy's Laboratories Ltd. Preparation of febuxostat
TWI606048B (zh) * 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物

Also Published As

Publication number Publication date
MX370375B (es) 2019-12-11
RU2017106058A3 (sl) 2018-08-28
LT3176165T (lt) 2018-11-26
BR112017001659A2 (pt) 2018-01-30
RS57797B1 (sr) 2018-12-31
PH12017500123A1 (en) 2017-05-29
MY179339A (en) 2020-11-04
WO2016017696A1 (ja) 2016-02-04
EP3176165A1 (en) 2017-06-07
EP3176165B1 (en) 2018-09-26
TWI687418B (zh) 2020-03-11
NZ729045A (en) 2022-05-27
PT3176165T (pt) 2019-01-10
AR101363A1 (es) 2016-12-14
TW201619153A (zh) 2016-06-01
EP3176165A4 (en) 2017-06-07
IL250144A0 (en) 2017-03-30
SA517380786B1 (ar) 2021-01-17
TR201818775T4 (tr) 2019-01-21
US9815826B2 (en) 2017-11-14
IL250144B (en) 2019-11-28
HRP20181789T1 (hr) 2018-12-28
DK3176165T3 (da) 2019-01-02
PH12017500123B1 (en) 2017-05-29
JP6230713B2 (ja) 2017-11-15
RU2675854C2 (ru) 2018-12-25
AU2015297489B2 (en) 2019-09-19
AU2015297489A1 (en) 2017-03-09
RU2017106058A (ru) 2018-08-28
CA2955485A1 (en) 2016-02-04
KR20170033321A (ko) 2017-03-24
MX2017000513A (es) 2017-04-27
CN106536519A (zh) 2017-03-22
CN106536519B (zh) 2019-03-29
ES2693382T3 (es) 2018-12-11
SG11201700742UA (en) 2017-03-30
CY1120933T1 (el) 2019-12-11
PL3176165T3 (pl) 2019-03-29
JPWO2016017696A1 (ja) 2017-04-27
ZA201700491B (en) 2018-04-25
US20170210735A1 (en) 2017-07-27

Similar Documents

Publication Publication Date Title
ZA201700304B (en) Spirocycloheptanes as inhibitors of rock
IL249345A0 (en) Disubstituted indazole compounds used as irak4 inhibitors
EP3102576B8 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
EP3200787A4 (en) Inhibitors of irak4 activity
EP3200788A4 (en) Inhibitors of irak4 activity
EP3200789A4 (en) Inhibitors of irak4 activity
EP3125895A4 (en) Substituted spirocydic inhibitors of autotaxin
EP3200790A4 (en) Inhibitors of irak4 activity
HK1245777A1 (zh) 用作nadph氧化酶抑制劑的氨基噻二唑衍生物
GB201416446D0 (en) New enzyme inhibitor compounds
EP3241822A4 (en) Urat1 inhibitor
EP3551625A4 (en) HETEROCYCLIC MCT4 INHIBITORS
HK1231484A1 (zh) 作為 和/或 的抑制劑的酰胺基取代的唑類化合物
HK1253572A1 (zh) 作為tnap抑制劑的吡啶並噁嗪酮化合物
EP3137541A4 (en) Polyurethane scorch inhibitor
HK1252767A1 (zh) 作為eaat3抑制劑的吡唑-吡啶衍生物
EP3526216C0 (en) BENZOTHIAZOLE DERIVATIVES AS DYRK1 INHIBITORS
HRP20181789T1 (hr) Kristal derivata azol benzena kao inhibitor ksantin oksidaze
EP3302493A4 (en) NEW USE OF CYSTINE-GLUTAMATE TRANSPORTER INHIBITOR
AU2016205137B2 (en) Furoquinolinediones as inhibitors of TDP2
HRP20182084T1 (hr) Derivat azol benzena i njegov kristal